Differences in HIV treatment experiences, perceptions, and behaviors by gender and sexual orientation in 25 middle-income and high-income countries: Findings from the 2019 Positive Perspectives Survey

Chinyere Okoli¹, Nicolas Van de Velde¹, Garry Brough²,³, W. David Hardy⁴, Giulio Maria Corbelli⁵, Brent Allan⁶, Marvelous Muchenje⁷, Erika Castellanos⁸, Benjamin Young⁹, Anton Eremin¹⁰, Pholokgolo Ramothwala¹¹, Patricia de los Rios⁷

AFFILIATION
1 ViiV Healthcare, Brentford Middlesex, United Kingdom
2 Positively UK, London, United Kingdom
3 UK Community Advisory Board (UK-CAB), London, United Kingdom
4 Division of Infectious Diseases, Johns Hopkins University School of Medicine, Johns Hopkins University, Baltimore, United States
5 European AIDS Treatment Group, Rome, Italy
6 International Council of AIDS Service Organizations (ICASO), Toronto, Canada
7 ViiV Healthcare, Quebec, Canada
8 Global Action for Trans* Equality (GATE)
9 ViiV Healthcare, Research Triangle Park, United States
10 AIDS Center Foundation, Moscow, Russia
11 Positive Convention Network, Cape Town, South Africa

CORRESPONDENCE TO
Patricia de los Rios. ViiV Healthcare ULC, 245 Armand-Frappier Boulevard Laval, Quebec H7V 4A 7, Canada. Email: patricia.x.delosrios@vivhealthcare.com

KEYWORDS
HIV, gender, treatment needs, men who have sex with men, disparities, men who have sex with women

Received: 12 September 2020, Revised: 18 October 2020, Accepted: 19 October 2020

ABSTRACT

INTRODUCTION Understanding differences in knowledge and behaviors among men who have sex with men (MSM), men who have sex with women (MSW), and women, is critical to tailor HIV treatment. We investigated these differences among an international sample of people living with HIV (PLHIV) in 25 countries.

METHODS Data came from the 2019 Positive Perspectives Study, an online convenience sample of PLHIV in 25 middle- and high-income countries. Participants were categorized as MSM (n=1018), MSW (n=479), or women (n=696), based on self-classified gender and sexual orientation. Descriptive and multivariable analyses were performed (p<0.05).

RESULTS Mean age was 43.4 years among MSM, 36.6 among MSW, and 41.0 among women. Overall, 24.2% [116/479] of MSW reported suboptimal health on all four domains assessed (sexual/mental/physical/overall), significantly higher than MSM (18.0% [183/1018], p=0.005), but similar to women (22.8% [159/696], p=0.585). Overall, the median number of reasons reported for missing HIV medication ≥1 time in the past month was 7, 2, and 1 for MSW, women, and MSM, respectively. The percentage reporting viral suppression among MSW (57.0% [273/479]) was significantly lower compared to both MSM (89.2% [908/1018], p<0.001), and women (62.8% [437/696], p=0.046). Yet, MSW were the least comfortable discussing with providers concerns about transmitting disease (MSW=42.8% [205/479]) vs MSM (70.3% [716/1018], p <0.001), or women (58.0% [404/696], p<0.001). The percentage of all MSW who considered having children a priority at time of starting treatment (30.5% [146/479]) was 1.4 times higher compared with women (22.6% [157/696], p=0.002) but about 6 times higher than MSM (5.4% [55/1018], p<0.001). Within multivariable analyses, being told of ‘Undetectable = Untransmittable’ by healthcare providers was positively associated with optimal sexual health among MSM in high-income countries (AOR=1.52; 95% CI: 1.01–2.32), MSM in middle-income countries (AOR=2.89; 95% CI: 1.57–5.32) and women in middle-income countries (AOR=2.89; 95% CI: 1.57–5.32) and women in middle-income countries (AOR=1.29; 95% CI: 1.04–1.60), but not among MSW in either middle- or high-income countries.

CONCLUSIONS Compared with MSM, women and especially MSW had greater unmet need – a previously unrecognized gap. Relatively low rates of viral suppression among MSW have implications for HIV transmission to women via heterosexual contact. Acknowledging these differences when planning and administering care can help address disparities.
INTRODUCTION

Some of the most consequential challenges reported among people living with HIV (PLHIV) are socially mediated, including stigma\(^1\) and may be differently perceived among men who have sex with men (MSM), men who have sex with women (MSW), and women, depending on social norms. For example, MSW may experience significant social stress at the intersection of their identities as PLHIV and MSM, especially in settings where being gay is criminalized or tabooed\(^2\). The psychosocial and emotional challenges faced by women living with HIV are multifaceted as women are more likely to be the caregivers, less educated, financially dependent, and at higher risk of inter-partner violence\(^2\). Understanding differences in perceived treatment needs by gender/sexual orientation is critical to tailoring treatment for better health outcomes. Solely exploring men–women differences, while important, may however mask underlying differences between MSM and MSW. This is a key concern because perceived treatment needs of MSW remain less understood, despite this group being the third largest population living with HIV, including many vulnerable groups such as people who inject drugs\(^3\). To fill this gap in knowledge, we performed comparative analyses among MSM, MSW, and women, using self-reported data for 2389 PLHIV in 25 middle- and high-income countries. We have previously reported some findings from these data in relation to polypharmacy, treatment adherence, patient–provider engagement, and aspirations towards improved HIV treatment\(^9-13\). In this work, however, we explore some of these themes from the perspective of disparities and health equity. Two fundamental questions were of interest. 1) What is the magnitude of the disparity in health-related outcomes by gender/sexual orientation? 2) Is the association between behavioral interventions (e.g., counseling about ‘Undetectable Equals Untransmittable’) and health-related outcomes different among MSM, MSW, and women? Elucidating these issues can inform patient care as well as public health decision-making regarding research, patient education, and healthcare priorities to help eliminate inequalities.

METHODS

Study population and sampling approach

This study, the 2019 Positive Perspectives (Wave 2), was from an online convenience sample of PLHIV living in 25 middle- and high-income countries. The first wave, conducted in 2017, comprised only high-income countries; the second wave was expanded to include 6 middle- and 19 high-income countries. Participating countries in the second wave, and sample sizes, were as follows: USA (n=400), South Africa (n=179), Russia (n=150), United Kingdom (n=123), Australia (n=120), Canada (n=120), France (n=120), Germany (n=120), Italy (n=120), Spain (n=120), Japan (n=75), Mexico (n=63), Portugal (n=60), Brazil (n=58), Switzerland (n=55), Taiwan (n=55), Netherlands (n=51), Argentina (n=50), Austria (n=50), Chile (n=50), China (n=50), Ireland (n=50), Belgium (n=50), Poland (n=50), and South Korea (n=50). Inclusion criteria for all participants were: 1) consenting adults aged 18–84 years, and 2) self-identified as being diagnosed with HIV and on antiretroviral treatment (ART) at the time of the survey. Of 7177 individuals screened during the wave 2 survey, 4203 were eligible, and 2389 completed the questionnaires (overall response rate: 57%). Ethical review was provided by the Pearl Institutional Review Board (#18–080622, covered all 25 countries) and the Sefako Makgatho Research Ethics Committee (for South Africa specifically, #SMUREC/M/223/2019).

Measures

Gender/sexual orientation status

Designation as MSM (n=1018), MSW (n=479), or women (regardless of sexual orientation, n=696), was derived from two separate variables for self-classified gender and sexual orientation. Individuals who identified their gender as ‘Man (including transman)’, and their sexual orientation as ‘Homosexual/Gay/ Lesbian’ were classified as MSM. Individuals who identified their gender as ‘Man (including transman)’ and their sexual orientation as ‘Heterosexual/straight’ were classified as MSW.

Health-related outcomes/experiences

Self-reported virologic control was defined as a response of ‘undetectable/suppressed’ to the question: ‘What is your most recent viral load?’ Polypharmacy was defined as taking ≥5 pills/day (for HIV or non-HIV conditions), or currently taking medicines for ≥5 medical conditions, including HIV. Suboptimal adherence was a report of ≥1 reason for which the individual missed HIV medication ≥5 times within the past month\(^10\). Data were also collected on willingness to share HIV status, and reasons for not sharing HIV status with others in the past. The survey further asked participants what issues they prioritized the most when they first started their HIV treatment, and what their current priorities were. Self-rated health was deemed optimal if self-classified as ‘Good’/‘Very good’. In addition, respondents provided information on various aspects of communication with their healthcare providers (HCPs), including whether ‘my provider has told me about “Undetectable = Untransmittable” (U=U)’ and whether they felt comfortable discussing with their HCP ‘concerns about the safety of others/preventing transmission’. Various barriers to discussing salient health issues with HCPs were assessed using the question: ‘Why, if at all, would you feel uncomfortable raising concerns with your main HIV care provider?’.

Statistical analyses

Prevalence estimates were calculated overall and by gender/sexual orientation within middle- and high-income countries separately (World Bank classification...
using per capita income). Comparisons of prevalence estimates were done with 2 tests (p≤0.05). Trends in self-reported diagnosis of various conditions by time since HIV diagnosis were explored using joinpoint and age-adjusted logistic regression. For each line segment in the joinpoint regression, we computed annual percentage change (APC) with 95% confidence intervals; estimates of average annual percentage change (AAPC) were used to summarize overall trends across all segments. We further used multivariable logistic regression to examine whether MSW-MSM and MSW-women differences remained significant after adjusting for HIV duration, underlying comorbidities, and various indicators of healthcare access. To determine whether the magnitude of the association between exposure to HCP-provided information about ‘Undetectable = Untransmittable’ and health-related outcomes differed by gender/sexual orientation, separate logistic regression analyses were performed among MSM, MSW, and women, each adjusting for education, employment, home ownership, age, year of HIV diagnosis, and country-specific human development index – a composite measure of life expectancy, education, and per capita income. Statistical analyses were with R Version 3.6.1.

**RESULTS**

Pooled data from middle- and high-income countries showed that mean (SD) age was 43.4 (12.2) years among MSM, 36.6 (10.6) among MSW, and 41.0 (11.9) among women. The percentage with >high school education was: MSM (80.1% [815/1018]), MSW (70.8% [339/479]), and women (70.1% [488/696]). The percentage who rented/owned their own housing was: MSM (78.0% [794/1018]), MSW (57.2% [274/479]), and women (63.5% [442/696]). The percentage employed was: MSM (71.9% [732/1018]), MSW (70.2% [336/479]), and women (67.7% [471/696]). In high-income countries, the median duration of HIV reported was: 9, 4, and 5 years for MSM, MSW, and women, respectively. In middle-income countries, the median duration was 3, 6, and 6 years for MSM, MSW, and women, respectively.

**Differential prevalence and trends in self-reported health outcomes**

Differential trends in self-reported diagnosis of non-HIV conditions were observed among MSM, MSW, and women, by time since HIV diagnosis (Table 1). Among MSM and MSW, self-reported diagnosis of anemia did not change significantly over time. However, for bone disease, insomnia, kidney disease, liver disease, mental conditions, and substance misuse, trends were significant and differed by gender/sexual orientation. For example, the percentage of women reporting insomnia increased significantly over time compared to MSM and MSW.

| Condition         | Group | 0–4 %  | 5–9 %  | 10–14 % | 15–19 % | 20–24 % | 25–29 % | ≥30 % | AAPC (unadjusted) | Age adjusted p-trend |
|-------------------|-------|--------|--------|---------|---------|---------|---------|-------|-------------------|----------------------|
| **Anemia**        | MSM   | 6.9    | 8.1    | 5.8     | 9.1     | 9.2     | 6.7     | 11.4  | 6.5 (-1.5 to 15.1) | 0.745                |
|                   | MSW   | 6.9    | 12.7   | 5.7     | 5.0     | 12.5    | 36.4    | 7.1   | 22.7 (-6.0 to 60.1)| 0.214                |
|                   | Women | 13.5   | 22.3   | 16.4    | 17.1    | 19.6    | 45.2    | 28.3  | 17.6 (3.2 to 34.0) | <0.001               |
| **Bone disease**  | MSM   | 1.7    | 1.9    | 8.0     | 10.9    | 14.5    | 10.0    | 27.8  | 49.9 (25.0 to 79.7) | <0.001               |
|                   | MSW   | 2.7    | 3.9    | 2.9     | 2.5     | 6.3     | 18.2    | 42.9  | 56.0 (25.5 to 94.0) | 0.007                |
|                   | Women | 3.1    | 3.2    | 2.7     | 11.4    | 15.2    | 26.2    | 39.1  | 56.4 (42.7 to 71.3) | <0.001               |
| **Insomnia**      | MSM   | 9.2    | 7.6    | 21.9    | 26.4    | 19.7    | 28.3    | 30.4  | 23.0 (7.2 to 41.2)  | <0.001               |
|                   | MSW   | 8.4    | 9.8    | 8.6     | 20.0    | 12.5    | 18.2    | 7.1   | 16.3 (-2.1 to 38.0) | 0.869                |
|                   | Women | 8.0    | 14.9   | 20.5    | 18.6    | 23.9    | 28.6    | 43.5  | 28.3 (18.6 to 38.8) | <0.001               |
| **Kidney disease**| MSM   | 0.9    | 1.9    | 1.5     | 1.8     | 6.6     | 8.3     | 16.5  | 62.3 (42.9 to 84.4) | 0.002                |
|                   | MSW   | 3.1    | 3.9    | 5.7     | 7.5     | 12.5    | 27.3    | 7.1   | 41.8 (18.5 to 69.7) | 0.036                |
|                   | Women | 2.8    | 4.3    | 5.5     | 4.3     | 8.7     | 9.5     | 6.5   | 21.2 (7.9 to 36.0)  | 0.025                |
| **Liver disease** | MSM   | 4.9    | 9.0    | 10.2    | 10.9    | 15.8    | 18.3    | 21.5  | 24.7 (16.6 to 33.4) | 0.013                |
|                   | MSW   | 6.1    | 3.9    | 2.9     | 12.5    | 37.5    | 54.5    | 57.1  | 52.7 (30.2 to 79.0) | <0.001               |
|                   | Women | 4.0    | 5.0    | 11.0    | 11.4    | 17.4    | 28.6    | 52.2  | 52.4 (43.5 to 61.9) | <0.001               |
| **Mental conditions** | MSM | 17.1 | 22.4 | 33.6 | 40.9 | 26.3 | 36.7 | 35.4 | 12.9 (-0.6 to 28.3) | 0.001                |
|                   | MSW   | 5.4    | 8.8    | 2.9     | 7.5     | 25.0    | 27.3    | 14.3  | 29.9 (6.5 to 58.4)  | 0.004                |
|                   | Women | 8.3    | 19.1   | 24.7    | 22.9    | 30.4    | 31.0    | 41.3  | 25.0 (11.2 to 40.5) | <0.001               |
| **Substance misuse** | MSM | 4.9 | 5.2 | 13.9 | 10.0 | 10.5 | 3.8 | 13.9 | 16.0 (-3.4 to 39.4) | <0.001               |
|                   | MSW   | 4.2    | 5.9    | 2.9     | 15.0    | 37.5    | 45.5    | 35.7  | 54.3 (29.7 to 83.6) | <0.001               |
|                   | Women | 4.3    | 4.3    | 12.3    | 17.1    | 15.2    | 14.3    | 19.6  | 27.4 (0.8 to 60.9)  | <0.001               |

MSM: men who have sex with men. MSW: men who have sex with women. a To test for trends, joinpoint regression analyses were performed. For each line segment in the joinpoint regression, we used NCI’s Joinpoint 4.0.1 software to compute annual percentage changes (APCs) with 95% confidence intervals; average annual percentage changes (AAPC) were computed to summarize overall trends across all segments. To allow robust estimates, duration of HIV was coded in intervals of 0–4, 5–9, 10–14, 15–19, 20–24, 25–29, and ≥30 years. b Adjusted trends were assessed in a binary logistic regression model controlling for age.
by duration of HIV; among women however, the percentage reporting anemia increased from 13.5% (44/325) for 0–4 years to 28.3% (13/46) for ≥30 years since HIV diagnosis (p-trend <0.001). Prevalence of self-reported diagnosis of insomnia increased significantly among MSM (AAPC=23.0, p<0.001) and women (AAPC=28.3, p<0.001) but did not change significantly among MSW. Self-reported diagnosis of kidney, bone, and liver conditions, as well as mental illness and substance-use disorder, increased significantly with increasing HIV duration among all groups (all age-adjusted p-trend <0.05) (Table 1). Overall, 24.2% [116/479] of MSW reported suboptimal health on all four domains assessed (sexual/mental/physical/overall), significantly higher compared to MSM (18.0% [183/1018], p=0.005), but not significantly different from women (22.8% [159/696], p=0.585). Examination of the individual health domains showed that, compared to MSW, MSM reported significantly lower prevalence of optimal physical (51.6% [247/479] vs 67.0% [682/1018]), mental (45.3% [217/479] vs 62.6% [637/1018]), and overall health (52.6% [252/479] vs 63.6% [647/1018]), as well as viral suppression (57.0% [273/479] vs 89.2% [908/1018]) (all p<0.001). Women reported higher prevalence of optimal mental health (58.2% [405/696], p<0.001) and viral suppression (62.8% [437/696], p=0.046) than MSW as well. Difficulty swallowing pills among MSW (56.8% [272/479] was significantly higher compared to MSM (20.2% [206/1018]) and women (36.5% [254/696]) (all p<0.001). The median number of reasons reported for missing HIV medication ≥1 time in the past month was 7, 2, and 1 for MSW, women, and MSM, respectively, in the overall population, and 9, 4, and 3, respectively, among those who missed HIV medication ≥1 time in the past month. More MSW missed HIV medication for each of the assessed reasons than MSM or women (Figure 1).

The percentage who reported awareness of the number of medicines in their HIV regimen was significantly lower among MSW (64.3% [308/479]) than either MSM (80.4% [818/1018], p< 0.001) or women (72.1% [502/696], p=0.004). The percentage of all surveyed MSW who considered efforts to minimize ART side effects as a priority

Figure 1. Percentage who reported missing antiretroviral treatment 1+ or 5+ times within the past month, by reason reported among men who have sex with men, men who have sex with women, and women
when they first started treatment (44.7% [214/479]) was significantly lower compared to MSM (60.3% [614/1018]); also, more MSW (51.6% [247/479]) experienced side effects from their current HIV medication than MSM (35.4% [360/1018]) (all p<0.001). Differences with women were non-significant for both indicators above, related to side effects. Of those who experienced side effects, MSW (56.3% [139/247]) reported the highest percentage of those who missed HIV medication ≥1 time in the past month because of side effects, versus women (33.1% [113/341], p<0.001) or MSM (24.4% [88/360], p<0.001). Despite MSW reporting the lowest prevalence of any non-HIV comorbidities 'ever been diagnosed with by a doctor or other healthcare professional' (46.1% [221/479]) compared to either MSM (64.6% [658/1018]) or women (56.8% [395/696]) (all p<0.001), MSW reported a higher prevalence of polypharmacy (45.1%) compared to either MSM (38.5%, p=0.017) or women (38.2%, p=0.02) (Supplementary file Figure 1). The poorer results seen for MSW persisted even after adjusting for duration of HIV and various indicators of healthcare access.

**Differences in perceived stigma, and attitudes towards sexual/reproductive health**

Of those in a relationship within the pooled sample from middle- and high-income countries, MSW reported lower prevalence of sharing their HIV status with a spouse/significant other (70.1% [309/441]) compared to either MSM (79.0% [548/694], p=0.001) or women (75.5% [448/593], p=0.049). Overall, 48.9% [234/479] of MSW worried that taking their HIV pills every day increased the chance of sharing their HIV status with others, significantly higher than either MSM (29.1% [296/1018], p<0.001), or women (41.4% [288/696], p=0.011). The percentage that had shared their HIV status with only their primary HIV care providers but no other person, was higher among MSW (19.6% [94/479]) versus MSM (7.9% [80/1018], p=0.001), but did not differ significantly from women (15.7% [109/696], p=0.077). The percentage that had shared their HIV status with their family doctor not providing HIV care, among those with one, was lowest for MSW (50.3% [229/455]) versus MSM (76.3% [704/923], p<0.001) or women (66.7% [444/666], p<0.001). Within stratified analysis, 62.7% [79/126] of MSW in middle-income countries had ever refused to share their HIV status for fear of being seen differently versus 46.5% [164/353] of MSW in high-income countries (p=0.002).

Among all participants regardless of HIV duration, the percentage of all surveyed MSW who considered having children as a priority at the time of starting treatment (30.5% [146/479]) was 1.4 times higher compared with women (22.6% [157/696], p=0.002) but almost 6 times higher compared with MSM (5.4% [55/1018], p<0.001) (Table 2). Women in high-income countries were significantly less likely to consider having children as a priority at the time of starting treatment (19.2% [95/495]) compared to women in middle-income countries (30.8% [62/201], p=0.001); for MSW and MSM, no significant differences existed between middle- and high-income countries. Among the subset of the population who had been diagnosed for ≥1 year, changes in perceived priorities between the time of starting treatment versus the time of the survey differed by gender/sexual orientation and regionally (Supplementary file Table 1 and Supplementary file Figure 2). For example, the

### Table 2. Self-rated health and treatment experiences among men who have sex with men (N=1018), men who have sex with women (N=479), and women (N=696) living with HIV in 25 countries, 2019

|                          | All men (N=1301) | MSM (N=322) | MSW (N=859) | All women (N=495) |
|--------------------------|-----------------|------------|------------|-----------------|
| **Self-rated health**     |                 |            |            |                 |
| Self-reported viral suppression | 78.6 | 78.6 | 89.9 | 85.5 |
| Optimal physical health   | 60.6 | 64.0 | 66.1 | 71.7 |
| Optimal mental health     | 55.3 | 64.0 | 60.8 | 72.3 |
| Optimal sexual health     | 46.0 | 57.1 | 47.3 | 64.2 |
| Optimal overall health    | 58.5 | 62.7 | 61.9 | 72.3 |
| Reported polypharmacy     | 42.8 | 33.1 | 39.1 | 35.3 |
| Reported any non-HIV comorbidity | 58.3 | 61.8 | 64.8 | 63.5 |
| Reported suboptimal treatment adherence | 21.4 | 27.0 | 14.8 | 19.5 |
| Difficulty swallowing pills | 31.1 | 33.5 | 20.3 | 20.1 |
| Perceive that HIV has an overall negative impact on their life | 39.6 | 34.8 | 39.7 | 37.1 |
| Satisfied with current HIV medication | 73.4 | 65.2 | 79.2 | 69.2 |

Continued
Table 2. Continued

| People with whom PLHIV have shared their HIV status | All men | MSM | MSW | All women |
|---------------------------------------------------|--------|-----|-----|----------|
| Spouse/significant other                          | 75.1   | 78.4| 78.3| 82.1     | 68.4 | 74.4| 73.2| 81.4 |
| Casual sex partners                                | 66.5   | 52.9| 73.1| 63.8     | 50.2 | 39.0| 55.9| 52.1 |
| Parents, siblings, and children                   | 65.5   | 62.6| 67.4| 60.5     | 59.8 | 62.1| 73.3| 79.8 |
| Close friends                                     | 74.1   | 70.5| 82.8| 84.0     | 52.5 | 53.3| 64.3| 73.0 |
| Wider family/circle of friends                    | 51.0   | 35.3| 58.9| 37.2     | 32.9 | 32.2| 41.9| 46.8 |
| Family doctor not providing HIV care              | 70.0   | 60.3| 79.5| 57.4     | 47.2 | 59.5| 64.8| 71.5 |
| Other HCPS not providing HIV care                 | 62.8   | 57.8| 72.5| 61.1     | 40.0 | 52.9| 54.5| 65.6 |
| Most of the people in my life                     | 30.5   | 20.1| 35.2| 21.7     | 20.4 | 20.2| 28.2| 35.7 |
| Co-workers                                        | 35.9   | 28.8| 40.0| 30.2     | 28.4 | 28.1| 30.5| 41.5 |

Reasons for which PLHIV ever refused to share their HIV status

- It has not been necessary/relevant to my daily interactions: 41.4, 49.7, 46.4, 49.1, 30.0, 50.8, 32.1, 31.8
- I was worried that they would see or treat me differently: 57.8, 64.6, 62.5, 67.3, 46.5, 62.7, 54.5, 61.7
- I was worried that they might then disclose my HIV status to others: 51.5, 61.5, 54.5, 67.3, 45.0, 54.8, 44.4, 55.2
- I was worried that I might be excluded from activities: 35.1, 47.2, 34.6, 48.4, 37.4, 46.8, 43.6, 31.3
- I was worried about being denied access to health care services: 16.1, 19.9, 14.9, 20.1, 20.4, 19.0, 21.4, 21.9
- I was worried about being denied access to financial benefits/support: 19.2, 14.6, 18.2, 12.6, 21.8, 15.1, 18.2, 13.9
- I was worried it might affect my friendships: 45.3, 48.8, 46.7, 50.3, 40.8, 50.8, 47.7, 43.8
- I was worried I might lose my job: 30.8, 38.2, 31.5, 47.2, 29.2, 32.5, 42.0, 30.3
- I was worried it might affect my romantic or sexual relationships: 39.4, 46.3, 45.8, 47.8, 25.5, 43.7, 25.9, 36.8
- I was worried about my physical safety: 20.0, 20.5, 18.6, 22.0, 21.5, 18.3, 19.0, 22.9
- I was worried about criminal prosecution: 11.6, 8.1, 8.8, 6.9, 19.5, 7.9, 10.1, 5.0

Treatment priorities at treatment initiation

- To ensure side effects would be minimal: 55.3, 57.1, 59.7, 63.5, 43.1, 49.2, 47.1, 51.2
- To ensure that the virus was suppressed enough so that I could not pass it on to a partner: 49.9, 55.9, 53.0, 65.4, 41.9, 43.7, 38.2, 57.7
- To minimize the long-term impact of HIV treatment: 45.6, 41.6, 48.4, 37.7, 38.0, 46.0, 38.6, 39.3
- To manage symptoms or illnesses caused by HIV: 50.7, 56.2, 53.6, 53.5, 42.5, 61.1, 47.9, 55.7
- To keep the number of HIV medicines in my treatment to a minimum: 34.4, 39.4, 34.5, 35.2, 32.9, 41.3, 33.9, 30.3
- To allow flexibility as to when I have to take the HIV medication (time of day, with or without food, etc.): 35.5, 40.4, 37.3, 44.0, 31.2, 34.9, 28.9, 40.3
- To ensure it was compatible with other medications/drugs/pills I was taking: 31.4, 26.7, 29.5, 25.2, 34.6, 28.6, 32.3, 28.9
- That the treatment is available in my public health facility: 26.7, 50.9, 25.4, 62.3, 30.6, 31.7, 21.6, 47.3

Continued
absolute change in perceived importance of preventing HIV transmission to a partner, when comparing time of starting treatment versus the time of the survey, respectively, was positive (i.e. an increase) among the following three groups: MSM in high-income countries (52.4% [432/825] vs 67.5% [557/825], p<0.001), MSW in middle-income countries (43.6% [51/117] vs 70.9% [83/117], p<0.001), and women in high-income countries (37.5% [173/461] vs 50.8% [234/461], p<0.001). Conversely, no change between the two time points was seen among MSM and women in middle-income countries, as well as MSW in high-income countries.

Among all MSM and women surveyed, those in high-income countries were more likely to be told of ‘Undetectable = Untransmittable’ by their HCP than their counterparts in middle-income countries (MSM: 73.1% [628/859] in high-income countries vs 56.6% [90/159] in middle-income countries, p<0.001; women: 68.9% [341/495] in high-income countries vs 54.2% [109/201] in middle-income countries, p<0.001). For MSW, the percentage who reported discussing ‘Undetectable = Untransmittable’ with their HCP was similar between high-income countries (57.5% [203/353]) and middle-income countries (57.9% [73/126], p=0.933) (Table 3). Women in middle-income countries were one of the groups to benefit the most from discussing ‘Undetectable = Untransmittable’ with their HCP; positive associations ranged from: feeling more ‘comfortable sharing’ their HIV status (AOR=2.89; 95% CI: 1.41–5.95); reduced fear of HIV-related discrimination in the workplace (AOR=0.46; 95% CI: 0.22–0.95) or in healthcare settings (AOR=0.59; 95% CI: 0.37–0.94); optimal sexual health (AOR=1.29; 95% CI: 1.04–1.60); belief that HIV treatment prevents transmission (AOR=5.18; 95% CI: 1.67–16.11); reduced odds of suboptimal adherence (AOR=0.34; 95% CI: 0.14–0.83); and increased odds of self-reported viral suppression (AOR=2.82; 95% CI: 1.20–6.64) (Table 4). The observed benefits of discussing ‘Undetectable = Untransmittable’ with HCPs among MSM in high-income countries included a combination of clinical and social outcomes, whereas for middle-income countries it was mostly social outcomes. For example, among MSM in high-income countries, discussing ‘Undetectable = Untransmittable’ with HCPs was associated with reduced odds of suboptimal adherence (AOR=0.55; 95% CI: 0.39–0.77), as well as higher odds of: belief that HIV medication prevented HIV transmission (AOR=2.22; 95% CI: 1.59–3.11); self-reported viral suppression (AOR=2.37; 95% CI: 1.42–3.97), optimal sexual health (AOR=1.52; 95% CI: 1.01–2.32), and sharing of HIV status with a spouse/partner (AOR=2.40; 95% CI: 1.42–4.07), close friends (AOR=1.90; 95% CI: 1.17–3.08), wider circle of family/friends (AOR=1.55; 95% CI: 1.02–2.35), and ‘most of the people in my life’ (AOR=1.55; 95% CI: 1.25–1.93). Among MSM in middle-income countries, discussing ‘Undetectable = Untransmittable’ with HCPs was not significantly associated with treatment adherence or viral suppression, but was significantly associated with belief that ART prevented HIV transmission (AOR=2.47), optimal sexual health (AOR=2.89), and increased willingness to share HIV status with close family (AOR=1.50), wider circle of family/friends (AOR=1.74), family doctor (AOR=1.76), and coworkers (AOR=1.52), but not with a spouse/partner (AOR=0.44), the latter finding was seen among MSW in middle-income countries as well (all p<0.05) (Table 4). MSM in middle-income countries who reported discussing ‘Undetectable = Untransmittable’ with their HCP were less likely to withhold their HIV status in healthcare settings for fear of being denied treatment (AOR=0.20; 95% CI: 0.10–0.41).
Differences in information seeking behavior and communication with healthcare providers

Among the subset of participants who reported having concerns about the long-term impact of their HIV treatment in the past 12 months, MSM, MSW, and women reported similar rates of educating themselves by 'reading articles, forums, research or other information' (MSM=48.1% [377/783]; MSW=50.0% [173/346]; and women=45.7% [241/527], p=0.446). Similarly, the percentage who reported 'I have discussed my concern with my main HIV care provider' was not significantly different by gender/sexual orientation (MSM=36.4% [285/783]; MSW=43.6% [151/346]; and women=40.0% [211/527], p=0.061). However, the percentage who indicated 'I have talked to

Table 3. Relationship with healthcare providers among men who have sex with men (N=1018), men who have sex with women (N=479), and women (N=696) living with HIV in 25 countries, 2019

| Relationship with healthcare providers* | All men | MSM | MSW | All women |
|----------------------------------------|--------|-----|-----|-----------|
|                                        | N=1301 | N=322 | N=859 | N=159 | N=353 | N=126 | N=495 | N=201 |
| I am given enough information to be involved in making choices about my HIV treatment | 66.4 | 50.6 | 72.6 | 49.7 | 50.7 | 54.0 | 64.4 | 47.3 |
| I feel I understand enough about my HIV treatment | 73.8 | 65.5 | 79.5 | 71.7 | 60.1 | 56.3 | 71.7 | 62.2 |
| HCP seeks my views about treatment before prescribing an HIV medication | 66.9 | 50.9 | 69.6 | 45.9 | 61.2 | 54.0 | 65.7 | 43.8 |
| HCP asks me if I have any concerns about the HIV medication I am currently taking | 66.5 | 61.8 | 68.2 | 62.3 | 62.6 | 63.5 | 66.9 | 52.2 |
| HCP tells me about new HIV treatment options that become available | 62.3 | 47.2 | 64.0 | 40.9 | 58.9 | 57.1 | 64.8 | 39.8 |
| HCP asks me frequently about any side effects I might be experiencing | 63.6 | 60.6 | 66.9 | 62.9 | 55.8 | 56.3 | 64.2 | 54.2 |
| HCP has told me about 'undetectable = untransmissible' (U = U) | 68.7 | 58.1 | 73.1 | 56.6 | 57.5 | 57.9 | 68.9 | 54.2 |
| I would like to be more involved when it comes to decisions about my HIV treatment | 59.0 | 73.0 | 59.4 | 74.8 | 55.8 | 72.2 | 66.5 | 82.1 |
| HCP meets my personal needs and considers the things that are important to me | 70.5 | 62.4 | 76.0 | 63.5 | 59.2 | 62.7 | 65.9 | 58.7 |
| No perceived barriers to discussing with HCP | 32.9 | 24.8 | 43.2 | 28.9 | 8.8 | 21.4 | 26.7 | 28.9 |

Percentage comfortable discussing specific issues with HCP

| The impact HIV is having on my life generally | 59.0 | 52.8 | 66.0 | 56.6 | 43.6 | 50.8 | 54.7 | 56.2 |
| Preventing HIV transmission | 61.6 | 60.9 | 70.8 | 67.9 | 39.4 | 52.4 | 56.0 | 63.2 |
| My emotional well-being | 55.7 | 52.8 | 64.0 | 56.6 | 37.1 | 49.2 | 49.3 | 56.7 |
| Privacy/confidentiality concerns | 55.0 | 49.4 | 62.2 | 49.1 | 39.1 | 50.8 | 47.1 | 54.2 |
| Having children | 44.7 | 44.4 | 47.1 | 45.9 | 38.5 | 42.1 | 45.3 | 50.7 |
| Illnesses caused by HIV | 62.0 | 53.1 | 69.8 | 50.9 | 42.8 | 52.4 | 54.1 | 60.2 |
| Side effects | 64.0 | 54.7 | 73.7 | 56.0 | 41.4 | 51.6 | 58.4 | 59.2 |
| Drug-drug interactions | 63.9 | 59.3 | 73.0 | 63.5 | 43.9 | 53.2 | 58.0 | 51.7 |
| Long-term effects (e.g. problems with bones, kidneys, liver) | 62.1 | 53.1 | 71.9 | 57.2 | 38.8 | 48.4 | 57.4 | 53.7 |
| Missing medication | 58.8 | 55.3 | 67.8 | 56.0 | 36.0 | 54.0 | 55.6 | 49.8 |

MSM: men who have sex with men. MSW: men who have sex with women. HCP: healthcare provider. HIC: high-income country. MIC: middle-income country. Summed sample size for MSM and MSW is less than for all men (N=1623) because of missing/indeterminate information on sexual orientation. Countries were classified as high- or middle-income based on the World Bank classification that uses per capita gross domestic product. The middle-income countries were Argentina, Brazil, China, Mexico, Russia, and South Africa; all others were high-income countries. a Except where otherwise indicated, responses of ‘Agree’ or ‘Strongly agree’ were classified as a positive indication whereas responses of ‘Strongly disagree’, ‘Disagree’, or ‘Neither agree nor disagree’ were classified as dissenting responses. b A report of being comfortable discussing with HCP regarding health concerns was defined as a response of ‘Very comfortable’ or ‘Comfortable’ (vs ‘Neither comfortable nor uncomfortable’, ‘Uncomfortable’, or ‘Very uncomfortable’).
Table 4. Adjusted odds ratio with 95% CI of the relationship between a report of having discussed 'Undetectable = Untransmittable' with a healthcare provider, and various health-related outcomes among people living with HIV in 25 countries, 2019

| Outcome                                                                 | High-income countries (N=1839) |                                  | Middle-income countries (N=550) |                                  |
|------------------------------------------------------------------------|---------------------------------|----------------------------------|---------------------------------|----------------------------------|
|                                                                        | MSM                             | MSW                              | Women                           | MSM                             | MSW                              | Women                           |
| Shared status with spouse/significant other                            | 2.40 (1.42-4.07)                | 0.73 (0.29-1.85)                 | 1.59 (0.87-2.92)                | 0.44 (0.23-0.82)                | 0.64 (0.44-0.93)                 | 1.46 (0.81-2.64)                |
| Shared status with casual sex partners                                 | 1.26 (0.72-2.21)                | 0.88 (0.39-1.98)                 | 1.76 (1.12-2.76)                | 1.45 (0.85-2.50)                | 0.84 (0.36-1.94)                 | 1.03 (0.36-2.91)                |
| Shared status with parents, siblings, and children                     | 1.42 (0.93-2.17)                | 1.01 (0.42-2.42)                 | 1.49 (0.86-2.59)                | 1.50 (1.12-2.01)                | 1.14 (0.65-2.01)                 | 2.12 (1.44-3.11)                |
| Shared status with close friends                                       | 1.90 (1.17-3.08)                | 0.83 (0.45-1.52)                 | 1.68 (1.07-2.66)                | 1.12 (0.40-3.14)                | 1.19 (0.95-1.48)                 | 1.80 (1.07-3.03)                |
| Shared status with wider family/circle of friends                      | 1.55 (1.02-2.35)                | 0.94 (0.65-1.37)                 | 1.57 (1.02-2.44)                | 1.74 (1.29-2.34)                | 1.72 (0.65-4.53)                 | 0.93 (0.36-2.44)                |
| Shared status with family doctor not providing HIV care                | 1.33 (0.68-2.61)                | 1.43 (0.80-2.55)                 | 1.48 (0.81-2.69)                | 1.76 (1.05-2.94)                | 1.19 (0.56-2.57)                 | 1.68 (1.07-2.64)                |
| Shared status with other HCPS not providing HIV care                   | 1.67 (1.14-2.44)                | 0.82 (0.45-1.48)                 | 1.74 (1.12-2.72)                | 0.70 (0.35-1.38)                | 1.37 (1.04-1.80)                 | 1.49 (0.96-2.30)                |
| Shared status with co-workers                                          | 1.22 (0.89-1.68)                | 0.59 (0.40-0.85)                 | 1.24 (0.80-1.93)                | 1.52 (1.08-2.14)                | 0.70 (0.47-1.06)                 | 1.34 (1.02-1.75)                |
| Shared status with most of the people in my life                        | 1.55 (1.25-1.93)                | 1.19 (0.56-2.52)                 | 1.14 (0.73-1.79)                | 0.82 (0.56-1.21)                | 0.93 (0.30-2.90)                 | 1.16 (0.66-2.03)                |
| Ever refused to share status because 'It has not been necessary/relevant to my daily interactions' | 1.40 (0.97-2.03)                | 0.86 (0.59-1.24)                 | 1.20 (0.70-2.07)                | 0.74 (0.41-1.31)                | 1.47 (0.68-3.18)                 | 0.75 (0.58-0.98)                |
| Ever refused to share status because 'I was worried that they would see or treat me differently' | 1.14 (0.87-1.48)                | 1.23 (0.63-2.39)                 | 1.49 (0.94-2.36)                | 0.74 (0.50-1.11)                | 0.67 (0.20-2.27)                 | 0.81 (0.63-1.04)                |
| Ever refused to share status because 'I was worried that they might then disclose my HIV status to others' | 0.95 (0.71-1.28)                | 0.95 (0.64-1.40)                 | 1.35 (0.79-2.30)                | 0.49 (0.24-1.00)                | 0.97 (0.48-1.95)                 | 0.71 (0.39-1.29)                |
| Ever refused to share status because 'I was worried that I might be excluded from activities' | 0.72 (0.51-1.01)                | 1.15 (0.64-2.04)                 | 0.92 (0.56-1.51)                | 1.27 (0.55-2.93)                | 0.78 (0.37-1.66)                 | 1.13 (0.58-2.20)                |
| Ever refused to share status because 'I was worried about being denied access to health care services' | 0.73 (0.43-1.22)                | 1.13 (0.66-1.93)                 | 0.75 (0.42-1.37)                | 0.20 (0.10-0.41)                | 0.86 (0.25-2.90)                 | 0.59 (0.37-0.94)                |
| Ever refused to share status because 'I was worried about being denied access to financial benefits/support' | 0.98 (0.66-1.46)                | 1.05 (0.47-2.35)                 | 1.22 (0.70-2.12)                | 0.46 (0.19-1.13)                | 3.13 (0.60-16.40)                | 0.36 (0.23-0.56)                |
| Ever refused to share status because 'I was worried it might affect my friendships' | 1.05 (0.74-1.50)                | 1.12 (0.71-1.76)                 | 1.05 (0.63-1.76)                | 0.59 (0.31-1.14)                | 0.90 (0.39-2.09)                 | 0.80 (0.68-0.93)                |
| Ever refused to share status because 'I was worried I might lose my job' | 0.74 (0.54-1.02)                | 1.31 (0.74-2.33)                 | 1.03 (0.71-1.49)                | 0.77 (0.48-1.23)                | 1.60 (0.59-3.45)                 | 0.46 (0.22-0.95)                |
| Ever refused to share status because 'I was worried it might affect my romantic or sexual relationships' | 1.10 (0.81-1.48)                | 1.21 (0.75-1.95)                 | 1.22 (0.65-2.30)                | 1.19 (0.86-1.66)                | 3.30 (2.48-4.39)                 | 0.59 (0.26-1.32)                |
| Ever refused to share status because 'I was worried about my physical safety' | 0.75 (0.49-1.14)                | 1.22 (0.68-2.19)                 | 0.65 (0.35-1.22)                | 0.99 (0.36-2.73)                | 2.81 (0.71-11.17)                | 0.23 (0.13-0.39)                |
| Ever refused to share status because 'I was worried about criminal prosecution' | 1.13 (0.66-1.95)                | 1.70 (0.90-3.22)                 | 1.35 (0.64-2.85)                | 0.33 (0.16-0.66)                | 0.45 (0.09-2.17)                 | 0.62 (0.15-2.64)                |

Continued
HIV patient support groups/organizations’ was significantly higher among MSW (41.9% [145/346]) and women (38.5% [203/527]) than MSM (26.2% [205/783]) (all p<0.001). Women in middle-income countries reported lower use of patient support groups/organizations than their counterparts in high-income countries (29.4% [50/170] vs 42.9% [153/357], p=0.003).

Pooled analyses of participants in middle- and high-income countries revealed that although desire to be involved in making treatment decisions was no different between MSW (60.1% [288/479]) and MSM (61.8% [629/1018], p=0.538), significantly fewer MSW reported being involved in their HIV care compared to MSM. For example, a significantly lower percentage of MSW reported the following indicators, compared to MSM, respectively: ‘I am given enough information to be involved in making choices about my HIV treatment’ (51.6% [247/479] vs 69.1% [703/1018], p<0.001), ‘My provider seeks my views about treatment before prescribing an HIV medication’ (59.3% [284/479] vs 65.9% [671/1018], p=0.013), or ‘My provider asks me frequently about any side effects I might be experiencing with my HIV treatment’ (56.0% [268/479] vs 66.3% [675/1018], p=0.001). MSW had the lowest percentage of those with no perceived barriers to discussing health issues with their HCP (12.1% [58/479]) vs MSM (41.0% [417/1018], p<0.001) or women (27.3% [190/696], p<0.001). Of surveyed PLHIV who ever wanted a new medication different from the one they were on and who discussed with their HCP, a significantly higher proportion of MSW received the medication (80.1% [213/266]), compared to MSM (54.3% [191/352], p=0.001), or women (62.6% [174/278], p<0.001). Of those who were not prescribed the medication after discussing with their HCP, only two reasons differed significantly by gender/sexual orientation, both of which were highest among MSW: medication not covered by insurance (MSW=20.8% [11/53], MSM=5.6% [9/161], and women=9.6% [10/104], p=0.005). MSM overall reported less satisfaction with their current HIV medication than MSM (60.3% [289/479] vs 77.6% [790/1018], respectively, p<0.001); they were also less satisfied with the care they received from HCPs in relation to whether it met their personal needs (60.1% [288/479] vs 74.1% [754/1018], p<0.001). Furthermore, MSM were more likely than MSW to perceive room for improvement with their HIV medication (43.4% [208/479] vs 33.0% [336/1018], p<0.001). None of these indicators differed significantly between MSW and women.

**DISCUSSION**

We found significant differences among MSM, MSW, and women, in relation to HIV duration, treatment needs, perceived stigma, and self-efficacy in discussing salient issues with HCPs. MSW had poorer health outcomes in general, especially when compared to MSM. This is a new finding that adds to the body of global HIV research; many global studies we reviewed did not examine MSW specifically.15-20 Our results also showed that women presented needs that were not dissimilar to MSW in many respects. MSM appeared to be the most educated about HIV at the time of initiating ART, as they reported the highest percentage of those who prioritized key issues at that time of starting treatment. Furthermore, MSM were currently more health-literate and engaged, as evidenced by greater awareness of the number of medicines in their treatment, greater perceived comfort in discussing treatment challenges with HCPs, and greater overall involvement in care. Not surprisingly, MSW reported the highest prevalence of treatment adherence and virologic suppression efforts to narrow disparities by gender/sexual orientation must consider the overlapping and unique needs of MSW and women, and seek ways to address them. There is need to expand gender focus of public health programs and recognize the unmet and evolving needs of other groups.
For example, in the Healthy People 2020 targets for HIV in the United States, targets specific to MSM exist (e.g. HIV-14.2 ‘Increase the proportion of men who have sex with men (MSM) who report having been tested for HIV in the past 12 months’)\textsuperscript{21}. Lessons learned from such targeted interventions among MSM could be applied to groups that are currently disadvantaged, including MSW and women.

Despite a lower prevalence of non-HIV comorbidities, MSW reported poorer overall health, greater polypharmacy, and poorer virologic control. The report of fewer comorbidities ‘ever been diagnosed with by a doctor or other healthcare professional’ may possibly signal underdiagnosis, especially as studies have suggested higher rates of non-retention in care, having no access to care, or being un-insured among MSW\textsuperscript{22,23}. Furthermore, MSW in our study were the least likely to share their HIV status with HCPs who were not their main HIV care providers, which may potentially contribute to fragmented care. However, even when engaging with their main HIV care providers, our findings indicated several communication challenges of a two-way nature between MSW and their providers. For example, despite having a higher prevalence of side effects from HIV medications than MSM, MSW were less comfortable than MSM to discuss side effects with their HCPs; at the same time, more MSM than MSW reported that their HCPs frequently asked them about any ART side effects they may be experiencing. Poor adherence among MSW was multifactorial, emphasizing that treatment planning for MSW can only be optimized if lifestyle factors that disrupt adherence are carefully considered. HCPs need to have more open conversations with MSW about treatment challenges and alternatives, as well as the implication of poor adherence for transmission risk.

Our results further showed that MSW, despite deeming the prevention of onward HIV transmission as one of their top three treatment priorities, had the lowest prevalence of sharing their HIV status with their sexual partners. Furthermore, even though MSW prioritized having children as a key treatment goal to a greater extent than MSM and even women, over one-third of MSW did not believe that ART prevented disease transmission, while over 2 in 5 reported not discussing ‘Undetectable = Untransmittable’ with their HCP. Disease transmission among MSW and women are deeply intertwined as women are more likely to be infected through heterosexual contact\textsuperscript{24,25}. Differential peaks in age-specific HIV diagnosis rates have been noted between European males and females: rates were highest in men aged 25–29 years, versus the 30–39 years group for women\textsuperscript{4}. Being diagnosed with HIV during those ‘prime’ years in a woman’s life may have profound implications socially, professionally, physically, sexually, and emotionally\textsuperscript{26-29}. Many women living with HIV first learn about their HIV diagnosis during pregnancy, during which time treatment adherence may be particularly challenging\textsuperscript{3}. A holistic consideration of psychosocial and emotional outcomes, beyond virologic control, may improve quality of life as espoused in the fourth ‘0’ target and accelerate progress towards other national or international targets\textsuperscript{10,32}.

Our findings show that progress towards the UNAIDS 90-90-90 targets may vary among subgroups. For MSW who reported poor rates of treatment adherence and viral control, as well as poorer self-efficacy in communicating treatment challenges with HCPs, there may be challenges attaining the 3rd 90 target (viral suppression). For women in high-income countries, where the data suggested later age at diagnosis, there could be challenges with the 1st 90 target (diagnosis). Older age at diagnosis could mean either later infection in life, or a lag period between infection and diagnosis. The basis for concern about increased risk of HIV infection among older women is from research findings indicating decreased condom use among women in older age, possibly from the misperception that protection is no longer necessary as pregnancy may no longer be a concern during menopause\textsuperscript{33}. The array of differences identified in our study by gender/sexual orientation should be considered when planning or implementing interventions aimed at enhancing HIV care or prevention at all levels, including primary (preventing onward transmission), secondary (HIV screening among high-risk groups), and tertiary (HIV treatment and enhancing quality of life among PLHIV).

Strengths and limitations
The main strengths of this study are the use of a large international sample of persons living with HIV to examine gender differences in evolution of patients’ preferences in HIV care and perceived treatment needs. Yet, limitations exist. First, because of sample size limitations, we could not examine certain categories of gender/sexual orientation, including individuals identifying as bisexual, asexual, pansexual, or other identities. Furthermore, whereas men were analyzed in two separate categories of MSM and MSW, all women were analyzed in one category regardless of sexual orientation because of small sample size for women who have sex with women. Second, only associations can be drawn from the cross-sectional design. Third, the non-probabilistic sampling may limit generalizability. Finally, cultural/regional differences in openness regarding discussing issues of sexuality may introduce some social/cognitive biases for questions deemed to be of a personal nature.

CONCLUSIONS
Among respondents in this international survey, key differences by gender and sexual orientation were observed in disease onset, treatment needs, and aspirations. MSW in general had poorer health-related outcomes. More differences existed between MSW and MSM, than between MSW and women for several health-related outcomes. Furthermore, where differences existed, the MSW-women gap was smaller than the MSW-MSM gap. These disparities
underscore why a one-size-fits-all approach cannot yield optimal outcomes in patient care. Consideration should be given to patient concerns to help tailor treatment in a manner that improves their health-related quality of life.

REFERENCES

1. Stutterheim SE, Pryor JB, Bos AER, Hoogendijk R, Muris P, Schaalma HP. HIV-related stigma and psychological distress: The harmful effects of specific stigma manifestations in various social settings. AIDS. 2009;23(17):2353-2357. doi:10.1097/QAD.0b013e32832320dc

2. Marongiu A, Hope VD, Parry JV, Ncube F. Male IDUs who have sex with men in England, Wales and Northern Ireland: are they at greater risk of bloodborne virus infection and harm than those who only have sex with women?. Sex Transm Infect. 2012;88(6):456-461. doi:10.1136/sextrans-2011-050450

3. Misachi J. Countries Where Homosexuality Is Illegal. The World Atlas. https://www.worldatlas.com/articles/countries-where-homosexuality-is-illegal.html. Published November 20, 2018. Accessed January 8, 2020.

4. Orza L, Bewley S, Logie CH, et al. How does living with HIV impact on women's mental health? Voices from a global survey. J Int AIDS Soc. 2015;18(Suppl 5):20289. doi:10.7448/IAS.18.6.20289

5. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS. 2012;26(16):2039-2052. doi:10.1097/QAD.0b013e328359590f

6. Turan B, Buhdhwani H, Fazeli PL, et al. How does stigma affect people living with HIV? The mediating roles of internalized and anticipated stigma in the effects of perceived community stigma on health and psychosocial outcomes. AIDS Behav. 2017;21(1):283-291. doi:10.1007/s10461-016-1451-5

7. Campbell JC, Baty ML, Ghandour RM, Stockman JK, Francisco L, Wagman J. The intersection of intimate partner violence against women and HIV/AIDS: a review. Int J Inj Contr Saf Promot. 2008;15(4):221-231. doi:10.1080/17457300802423224

8. Risher K, Mayer KH, Beyrer C. HIV treatment cascade in MSM, people who inject drugs, and sex workers. Curr Opin HIV AIDS. 2015;10(6):420-429. doi:10.1097/COH.0000000000000200

9. Okoli C, de Los Rios P, Eremin A, et al. Relationship Between Polypharmacy and Quality of Life Among People in 24 Countries Living With HIV. Prev Chronic Dis. 2020;17:E22. doi:10.5888/pcd17.190359

10. de Los Rios P, Okoli C, Punekar Y, et al. Prevalence, determinants, and impact of suboptimal adherence to HIV medication in 25 countries. Prev Med. 2020;139:106182. doi:10.1016/j.ypmed.2020.106182

11. Okoli C, Brough G, Allan B, et al. Shared Decision Making Between Patients and Healthcare Providers and its Association with Favorable Health Outcomes Among People Living With HIV. AIDS Behav. 2020;1-12. doi:10.1007/s10461-020-02973-4

12. Okoli C, Van de Velde N, Richman B, et al. Undetectable Equals Untransmittable (U = U): Awareness and associations with health outcomes among people living with HIV in 25 countries. Sex Transm Infect. 2020. doi:10.1136/sxtrans-2020-054551

13. de Los Rios P, Okoli C, Young B, et al. Treatment aspirations and attitudes towards innovative medications among people living with HIV in 25 countries. Popul Med. 2020;2(1):1-13. doi:10.18332/popmed/124781

14. World Bank Country and Lending Groups. The World Bank. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Accessed November 2, 2020.

15. Mascolini M, Zuniga JM. Perceptions of health, HIV disease, and HIV treatment by patients in 6 regions: analysis of the 2555-person AIDS treatment for life international survey. Int J AIDS Care (Chic). 2008;7(4):160-177. doi:10.1177/1545109708322728

16. Nachega JB, Morroni C, Zuniga JM, et al. HIV treatment adherence, patient health literacy, and health care provider-patient communication: results from the 2010 AIDS Treatment for Life International Survey. J Int Assoc Physicians AIDS Care (Chic). 2012;11(2):128-133. doi:10.1177/1545109712437244

17. Nachega JB, Morroni C, Zuniga JM, et al. HIV-related stigma, isolation, discrimination, and serostatus disclosure: a global survey of 2035 HIV-infected adults. J Int Assoc Physicians AIDS Care (Chic). 2012;11(3):172-178. doi:10.1177/1545109712436723

18. Maman S, Abber L, Parker L, et al. A comparison of HIV stigma and discrimination in five international sites: the influence of care and treatment resources in high prevalence settings. Soc Sci Med. 2009;68(12):2271-2278. doi:10.1016/j.socscimed.2009.04.002

19. Genberg BL, Hlavka Z, Konda KA, et al. A comparison of HIV/AIDS-related stigma in four countries: negative attitudes and perceived acts of discrimination towards people living with HIV/AIDS. Soc Sci Med. 2009;68(12):2279-2287. doi:10.1016/j.socscimed.2009.04.005

20. Langebeek N, Gisolf EH, Reiss P, et al. Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med. 2014;12:142. doi:10.1186/1741-7015-12-142

21. U.S. Department of Health and Human Services. Increase HIV Testing and Prevent HIV Risk. https://www.healthypeople.gov/2020/topics-objectives/objective/hiv-142. Accessed January 8, 2020.

22. Zule WA, Bobashev GV, Wechsberg WM, Costenbader EC, Coomes CM. Behaviorally bisexual men and their risk behaviors with men and women. J Urban Health. 2009;86(Suppl 1):48-62. doi:10.1007/s11524-009-9366-3

23. Golin C, Marks G, Wright J, et al. Psychosocial characteristics and sexual behaviors of people in care for HIV infection: an examination of men who have sex with men, heterosexual men and women. AIDS Behav. 2009;13(6):1129-1142. doi:10.1007/s10461-009-9613-3

24. European Centre for Disease Prevention and Control, World
Health Organization Regional Office for Europe. HIV/AIDS surveillance in Europe 2018 - 2017 data. Copenhagen, DK: WHO Regional Office for Europe; 2018. https://www.ecdc.europa.eu/sites/default/files/documents/hiv-aids-surveillance-europe-2018.pdf. Accessed November 2, 2020.

25. Centers for Disease Control and Prevention. Diagnoses of HIV Infection in the United States and Dependent Areas, 2018 (Preliminary). Vol. 30. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2018-preliminary-vol-30.pdf. Published November 2019. Accessed November 2, 2020.

26. Kumar S, Gruskin S, Khosla R, Narasimhan M. Human rights and the sexual and reproductive health of women living with HIV - a literature review. J Int AIDS Soc. 2015;18(Suppl 5):20290. doi:10.7448/IAS.18.6.20290

27. Carlsson-Lalloo E, Berg M, Melgiren Å, Rusner M. Sexuality and childbearing as it is experienced by women living with HIV in Sweden: a lifeworld phenomenological study. Int J Qual Stud Health Well-being. 2018;13(1):1487760. doi:10.1080/17482631.2018.1487760

28. Craft SM, Delaney RO, Bautista DT, Serovich JM. Pregnancy decisions among women with HIV. AIDS Behav. 2007;11(6):927-935. doi:10.1007/s10461-007-9219-6

29. Kass NE. Policy, ethics, and reproductive choice: Pregnancy and childbearing among HIV-infected women. Acta Paediatr Suppl. 1994;400:95-98. doi:10.1111/j.1651-2227.1994.tb13344.x

30. UNAIDS. GLOBAL HIV STATISTICS Fact Sheet. https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. Accessed November 2, 2020.

31. Lazarus JV, Safreed-Harmon K, Barton SE, et al. Beyond viral suppression of HIV - the new quality of life frontier. BMC Med. 2016;14(1):94. doi:10.1186/s12916-016-0640-4

32. Global HIV targets. Avert website. https://www.avert.org/global-hiv-targets. Updated October 1, 2019. Accessed January 8, 2020.

33. Schick V, Herbenick D, Reece M, et al. Sexual behaviors, condom use, and sexual health of Americans over 50: implications for sexual health promotion for older adults. J Sex Med. 2010;7 (Suppl 5):315-329. doi:10.1111/j.1743-6109.2010.02013.x

ACKNOWLEDGMENTS
Data analysis and medical writing was supported by Zatum LLC.

CONFLICTS OF INTEREST
The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. The authors declare that they have no competing interests, financial or otherwise, related to the current work. E. Castellanos and B. Allan report personal fees from ViIV Healthcare during the conduct of the study, and personal fees from ViIV Healthcare outside the submitted work. N. Van de Velde reports grants from ViIV Healthcare and GlaxoSmithKline outside the submitted work. G. M. Corbelli reports personal fees from ViIV Healthcare during the conduct of the study, and personal fees from ViIV Healthcare and HIV Vaccine Trials Network outside the submitted work. W.D. Hardy reports personal fees from ViIV Healthcare, during the conduct of the study; and personal fees from ViIV Healthcare, Advisory Boards, Merck, and from Gilead Sciences, outside the submitted work. P. de los Rios and B. Young report grants from ViIV Healthcare during the conduct of the study, as well as outside the submitted work. A. Eremin and C. Okoli report personal fees from ViIV Healthcare, during the conduct of the study. P. de los Rios, C. Okoli, B. Young, M. Muchenje and N. Van de Velde are employees of ViIV Healthcare.

FUNDING
This work was sponsored by ViIV Healthcare.

AUTHORS’ CONTRIBUTIONS
CO, PD, BY and NV conceptualized the study. All authors contributed to the study design, analyses, drafting of the manuscript, and substantial revisions. All authors gave final approval for the manuscript to be submitted for publication.

PROVENANCE AND PEER REVIEW
Not commissioned; externally peer reviewed.